Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11762MR)

This product GTTS-WQ11762MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11762MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12927MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ6642MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ4570MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ8998MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ3331MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ467MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ8794MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ36MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW